(-0.02%) 5 477.50 points
(-0.04%) 38 803 points
(0.02%) 19 925 points
(0.29%) $80.56
(1.11%) $2.82
(0.13%) $2 332.10
(-0.31%) $29.30
(-0.14%) $969.50
(0.02%) $0.932
(-0.12%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens...
Stats | |
---|---|
Šios dienos apimtis | 1.62M |
Vidutinė apimtis | 2.42M |
Rinkos kapitalizacija | 268.70M |
EPS | $-0.840 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $-0.560 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-11.29 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00900 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-21 | Siegel Jay Philip | Buy | 16 500 | Stock Option (right to buy) |
2024-05-21 | Siegel Jay Philip | Buy | 6 500 | Restricted Stock Unit |
2024-05-21 | Chhabra Meenu | Buy | 17 077 | Stock Option (right to buy) |
2024-05-21 | Chhabra Meenu | Buy | 16 500 | Stock Option (right to buy) |
2024-05-21 | Chhabra Meenu | Buy | 6 500 | Restricted Stock Unit |
INSIDER POWER |
---|
40.12 |
Last 100 transactions |
Buy: 1 316 271 | Sell: 560 626 |
Tūris Koreliacija
MacroGenics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
FTNT | 0.816 |
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
MacroGenics Inc Koreliacija - Valiuta/Žaliavos
MacroGenics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $58.75M |
Bruto pelnas: | $40.88M (69.59 %) |
EPS: | $-0.150 |
FY | 2023 |
Pajamos: | $58.75M |
Bruto pelnas: | $40.88M (69.59 %) |
EPS: | $-0.150 |
FY | 2022 |
Pajamos: | $151.94M |
Bruto pelnas: | $144.56M (95.14 %) |
EPS: | $-1.950 |
FY | 2021 |
Pajamos: | $75.64M |
Bruto pelnas: | $72.99M (96.50 %) |
EPS: | $-3.30 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.